m gurdalaMikołaj Gurdała
Innovation and Regional Manager for North East Europe, EIT Health InnoStars.
Mikołaj Gurdała is an expert with extensive experience experienced in EU funds, technology transfer and R&D. He has considerable expertise of international affairs and cross-sectoral cooperation. With EIT Health, one of the biggest healthcare organisations in Europe, he is responsible for developing international joint ventures and innovative projects co-created with academia and industry partners. He was one of the founders of building in Europe so called InnoStars Region within the EIT Health organisation, with aims to develop digital health, medtech and biotech innovations in the emerging markets.  Before joining EIT Health, Mikołaj Gurdała was a CEO and co-founder of Flavopharma, as well as being a director for Research, Strategies and Development at the Medical University of Łódź. Fields of expertise: supporting new ventures and start-ups in the ICT and life sciences sector, IP management and strategic development, change management, mentoring and coaching.

p edwardsPaul Edwards MBE
Paul is the Managing Partner of Horton Global Healthcare, the healthcare arm of Horton International.
In his current role he has worked extensively in the UK, mainland Europe and Asia, with clients including major pharmaceutical companies, medical device organisations and early stage biotechnology companies. He has helped organisations to fill roles including Chairman, Chief Executive Officer and non-executive Directors, as well as senior Manufacturing, Operations, Commercial and R&D positions.
Prior to his career in Executive Search, he worked for Beecham Pharmaceuticals and Genzyme Corporation, where he headed the UK operations for the company. In 2000, he joined the UK based biosimilars’ organisation, GeneMedix plc as Chief Executive Officer, and successfully led a major funding round taking the company to a dual listing on the London and Singapore Stock Exchanges. More recently, Paul has acted as a NED to Goldshield Group plc and BioProducts Laboratories, and oversaw the sale of both organisations to Private Equity Groups.
Paul is a familiar face in the UK biotech arena, having been the Chairman of the UK BioIndustry Association’s Manufacturing Advisory Committee and was the recipient of the Donald Medal for services to Biochemical Engineering (1999). In 1997 he received an MBE for services to biotechnology.

k jarosinskaKarolina Jarosińska
ExecMind/Founder and Managing Director
Karolina is the Founder and Managing Director of ExecMind, Life Science Executive Search company, based in Krakow, Poland. She has been working in the recruitment industry for over 15 years and possesses significant experience in talent acquisition for senior scientific and C-level positions on European market. In 2015, she started ExecMind, and 4 years later, the company is a leader in scientific and executive recruitment in Poland for biotech, biopharma and medtech industries. The company is a member of internationally-recognized Life Sciences clusters.
Karolina holds a MA degree in sociology from the University of Szczecin. She continued her education by attending postgraduate studies in Human Resources, and in 2014/2015 she has completed another one-year postgraduate course on Business in Biotechnology (Jagiellonian University joint with Jagiellonian Centre of Innovation, Krakow, Poland). Karolina also successfully finished international courses in drug discovery and development.
Karolina is actively involved in integrating Life Science community in Poland. As a member of Life Science Cluster in Krakow, she supports and promotes cluster activities within biotech, pharma and medtech communities on the international stage.

m gwizdaMichał Gwizda
Managing partner at CRIDO | Business & innovations
Michał is the managing partner at Business and Innovation Team at CRIDO. He specializes in consulting projects regarding innovation and R+D. Michał works with companies at different stages of their innovation-based growth, and seamlessly combines various consulting capabilities from the realm of innovation, finances, taxes and public aid. He is at the helm of a team of 40 professionals, which for many
years now has regularly received accolades, from FORBES, among others, for its performance as the leader in obtaining EU funds in Poland. Michał has been in professional practice since 2002, specializing in
business consulting regarding public aid, innovation and EU funds. He started off his career in the Ministry of Finance and in one of the Big Four firms. He joined CRIDO at the very outset of our operations. He has been engaged in the process of molding Poland’s innovation policy and streamlining the administration’s abilities regarding the use of public funds.

r landesRonald Landes
Mr. Landes founded and led Landes Bioscience, publisher of 50 peer-reviewed life science journals, for 20 years. Currently he is CEO of the early-stage liver therapeutics start-up, von Baer Wolff, and serves on the board of directors and scientific advisory boards of several organizations. He has invested in approximately 25 early-stage life science companies in the US, Europe and Israel. Mr. Landes has a BS in biochemistry from the University of Chicago, an MD from the Medical College of Wisconsin and trained in surgery at the University of Minnesota.

r kozlowskiRoland Kozłowski
Roland received a first class hon¬ours degree from the University of Bath and a PhD from the University of Cambridge. He is a serial bio-entrepreneur, investor and mentor who has worked in the industry for over twenty five years. Roland was Chief Executive Officer of Lec-tus Therapeutics and Sense Proteomic Limited two venture capital backed companies which he founded, built and sold. During his career Roland has lead or played a key role in a many transactions including company financing, sale, purchase, financing and in- and out-licensing with a cumulative value of over $200m. Earlier in his career Roland ran Research Groups at the University of Oxford and University of Bristol where he published and patented in the life science field. He has been a Visiting Industrial Professor, served on, or advised the boards of several European companies and organizations including the Bio-Industry Association in the UK. Presently he is President and owner of Life Science Biznes Consulting which specializes in commercializing technology from emerging economies particularly in Poland. He has acted as an advisor to the National Centre of Research & Development in Poland and the Polish Development Agency. He is a founder and limited partner in Life Science Innovations a specialist VC fund based in Poland and a director or mentor to a number of start-up companies.

s powellSteven Powell
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen.
He has over 30 years of operational and investment experience in pharmaceutical, diagnostics and medtech R&D. His operational experience includes appointments with Beecham Pharmaceuticals (GSK), Whatman, Celsis, Active Biotech, KS BioMedix, Plethora Solutions and Cambridge Cognition. In 2003 he joined Gilde Healthcare in the Netherlands, a pan-European life sciences investment fund where he continued to serve as an adviser to the fund until 2016.
He has extensive licensing and M&A experience and has raised finance in both public markets and through private equity and venture capital. He is currently CEO of eTheRNA Immunotherapies NV in Belgium and Chairman of UK public company, Cambridge Cognition Holdings PLC.

t weightmanTracy Weightman
Principal, Bridge Valley Ventures.
Tracy Weightman is a Principal at Bridge Valley Ventures and has over 15 years’ experience in venture capital, business development and project management. Tracy was previously an Investment Associate at Epidarex Capital, a £50m UK-based life science venture fund. During her time there she played a key role in the closure of four large Series A investments and several bridge financings. She was a key part of the team involved in the creation of Nodthera Ltd, which was based on research and development at Selvita SA. Prior to Epidarex, Tracy worked in business creation and business development functions at Edinburgh University and as a project manager for Quintiles, where she gained a strong track record in drug development. Tracy holds a BSc in Chemistry and an MBA, both from the University of Strathclyde.

j borgJohn J Borg, PhD
Pharmacist, specialised in Pharmacology currently serves as a Director at the Maltese Medicines Agency (ADM) and is responsible for EU centralised medicinal productevaluations; scientific advice and clinical
trials at the Maltese Medicines Agency.
Prof. Borg's professional trajectory has touched several areas of expertise from pre-clinical study to clinical activity as well as R&D of Ion Channel modulators,along with his commitment to teaching and regulatory activity, such as: national and international regulatory activities for the European union; preparation, evaluation and coordination of Research Projects; participation in international bodies etc.
Maltese member of the Committee for Human Medicinal Products (CHMP); member of the Committee on Advanced therapies (CAT); member of the Pharmacovigilance Risk AssessmentCommittee (PRAC); Member of the Paediatric Committee (PDCO); Co-Chair of the European Union Pharmacovigilance Oversight Group and member of the biologics working party (BWP) at the European Medicines Agency.
John J Borg trained at the University of Bristol and has published numerous scientific publications as well as chapters in books.

m olejniczakMariusz Olejniczak
CEO WPD Pharmaceuticals Sp. z o.o
Mariusz Olejniczak, WPD's Chief Executive Officer, has significant scientific and technical expertise. Mr. Olejniczak is an experienced clinical research professional with significant expertise in the oncology, infectious diseases and electronic health record. He has over 12 years of extensive experience in facilitating clinical research, project development and implementation. He has expertise in cooperation with pharma and biotech companies in Poland and aboard including consulting in strategy and created two e-clinical start-ups. He is a member of the board and supervisory board of several research and development companies. Mr. Olejniczak previously served as Director of Sales and Feasibility for Pratia Inc., as Director of Development at Bioscience SA and as a clinical development consultant to various other entities. He is a graduate in biotechnology at the University of Life Sciences in Poznań and is currently a PhD candidate at Kozminski University in Warsaw, Poland.
WPD is a privately-held biotechnology research and development company. WPD operates in the pharmaceuticals industry with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

p wielgusPaweł Wielgus, PhD
Biotechnologist, PhD in chemical sciences, financial analyst and investor. He has many years of experience in management, establishing and developing technological start-up’s. An expert and active practitioner in the field of commercialization of Scientific research in Life Sciences.
MSc Eng. in biotechnology (Wroclaw University of Technology, 2004), financial analyst (Wroclaw University of Economy, 2009), PhD in chemistry (Wroclaw University of Technology, 2010). Participant of the International Max Planck Research School, a prestigious international PhD program (2005-2008). Beneficiary of a research grant awarded by the Committee for Scientific Research (2009-2010). Scientific consultant and trainee at the Jackson State University, Mississippi, USA (2004, 2005) and the Max Planck Institute for Solid State Physics, Dresden, Germany (2005-2007). Participant of numerous conferences, workshops and symposia organized among others by the Universities of Palermo, Valencia , Helsinki and Geneva. Author and co-author of several scientific papers published in leading international journals. In the past professionally linked to Wroclaw Research Centre EIT+ Ltd., initially as Business Coach (3.1 Operational Program Innovative Economy VC fund, 2010), then as Key Account Manager in Life Sciences Dept. (2011-2012) and finally as Deputy Director of Business Development Department for Commercialization and Intellectual Property Management (in charge of 3.1 Operational Program Innovative Economy VC fund; responsible for corporate governance and commercialization of results of scientific research carried out in Biotechnology and Nanotechnology Depts., 2013). Chairman of the Audit Committee in the Association of Individual Investors, the largest organization of private investors in the CEE region (since Oct. 2011). In the past also an employee in the Association of Individual Investors, initially as a specialist in Legal Dept. and then as Director for Legal Dept. (2008-2010). Member of supervisory boards of companies listed on the Warsaw Stock Exchange: Lentex SA (2009-2011) and Plastics Processing Plast-Box SA (2011-2012). Chairman of the Board in Lentex ChemFund Management Ltd. (2010-2011). Former member of supervisory boards of several start-up companies (Simply User, Nanovectors, InnovaLab, Incuvo, Lipid Systems). Qualified for the Top500 Innovators program organized under the auspices of the Ministry of Science and Higher Education (2012). Lecturer at the Higher School of Banking in Wroclaw ("Models of commercialization of the intellectual property", 2012) as well as at the International School of Logistics and Transport in Wroclaw ("Commercialization as a path to success", 2012). Experience supported by in-depth analyses of over one hundred of scientific research projects and successful transactions of investments and exits concerning start-up companies. Certified Adviser in the alternative trading system New Connect in Warsaw (since 2012).

r watsonDr Robert Watson
Rob was most recently a Managing Director at Altaris Capital Partners, a leading healthcare-focused private equity firm based in New York, where he led the firm's investments in the pharma and life sciences sectors.
He has broad experience investing across the healthcare and technology industries, in companies based in Europe, the US and in Asia. Prior to Altaris, he worked at HgCapital in London, Ares Life Sciences in Geneva, and Sofinnova Partners in Paris.
Before investing Rob was a neuroscientist and has published research into neurodegenerative diseases. He has an MBiochem in Biochemistry and a DPhil in Neurology from the University of Oxford.

t sedgwickProf Tony Sedgwick PhD FRCPath
The Thought Disruptor
Tony is a life Science Strategist and Freelance Science /Business Professor .Originally an academic pathologist ,part of the linage of Eli Metchnikoff. After a number of senior jobs in Research and development at Roche Tony became CEO of four Biotech companies and chairman of many. Following establishing the Pierre Fabre Fund for innovation the corporate venture firm ,Tony has developed his model of being a modern "Eminence Gris" helping CEO CSOs , entrepreneurs and inventors as a trusted advisor and helping their minds to work through strategy in a systematic way .Tony is an active systemic constellation psychotherapist ,thought disruptor and talent finder .He recently launched the Agile life science co creative workshop as a thought leadership series throughout the Uk and Europe.

p przewiezlikowskiPaweł Przewięźlikowski
Chief Executive Officer, Ryvu Therapeutics S.A.
Mr. Pawel Przewiezlikowski, co-founded Selvita in 2007 and is the Chief Executive Officer of the company, responsible for strategic management, business and corporate development. He is also the President of
Supervisory Board at Ardigen and Chief Executive of BioCentrum, Selvita's daughter companies.
Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region. He was awarded Knight's Cross of the Order of Polonia Restituta for his contributions to the development of Poland's business environment, as well as, EY Entrepreneur of the Year 2015 award in the New Technologies/Innovation category in Poland.
From 1994 to 2007 he worked at Comarch, a Polish information technology company. As a management board member since 1996, he was responsible for the divisions offering solutions for the pharmaceutical, banking, manufacturing and services industries and took part in the organic transformation of a university spin-off to the largest organically grown IT company in Central and Eastern Europe, employing over 2 700 people in 20 countries. In 1999-2007 he was also the co-founder, the first CEO and then the Vice President of the Supervisory Board of Interia.pl, the third largest Internet portal in Poland.
Mr. Przewiezlikowski holds an MBA from the joint program of the Teesside University (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin.

f jelenFilip Jeleń, PhD, MBA
Founder & CEO at Pure Biologics Inc. and Captor Therapeutics S.A.
Serial entrepreneur with 15+ years of scientific and R&D managing experience, both in Poland and USA and over 9 years of experience in building start-ups. Received his PhD in biochemistry from the University of Wroclaw and executive MBA from the Polish-American Business School. Trained at the Institute for Molecular Medicine in Houston Medical Center, USA in the lab of Nobel Prize laureate, prof. Murad. Currently leads the business and operational activities of two drug development companies, coordinating teams of 170 specialists and having over 250 million PLN under management for ultra innovative R&D projects.
Captor Therapeutics is a fast-growing biopharmaceutical company, globally one of few focused on the development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known
treatment options. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”. Captor Therapeutics’ integrated competencies and expertise in biology and chemistry allow to perform all stages of early drug development.

d vitaDavid G. Vita
David has more than 30 years of corporate management experience holding top management positions in young companies that went from the idea to exit (Lead IP, Nilimed, EVR) and from receivership to become public (FLSN- TASE and TNOLF-NASDAQ). Formerly in charge of the strategic marketing in the 600M$ telecom access division of ECI. Also, through his consulting firm Makwa, has managed the Massachusetts State and Port Authorities Office of Business Development in Israel for 3 consecutive appointments - nine years. McKinsey & Co and PWC alumnus where he specialized in M&A for large food conglomerates and valuation of shipyards and EPC companies. He graduated in Statistics from The Haifa University and is fluent in Italian, French, English and Hebrew.

m treherneDr Mark Treherne
Chief Executive, Cellesce Limited
Mark obtained his PhD in pharmacology from Cambridge University and has over 25 years' experience in the discovery of novel treatments for diseases with unmet medical need. Mark formerly worked at Pfizer where he was responsible for research into neurodegenerative diseases and then set up Cambridge Drug Discovery as Chief Executive, which was then sold to BioFocus (now part of Charles River). Since then, Mark has worked with many early-stage biotechnology companies and, more recently, was Chief Executive of the Life Sciences Organisation of UK Trade & Investment, which helped UK-based Life Sciences companies raise investment and export overseas.

s ogrodzinskiStefan Ogrodzinski BSc (Hons), MBA
Stefan Ogrodzinski received his BSc (Hons) in Toxicology and Pharmacology from The School of Pharmacy, University College London, in 1987 and his MBA from De Montfort University in 1999.
Stefan's career has spanned the pharmaceutical industry, the healthcare sector, the voluntary sector and the educational sector, giving 30 years of sales, marketing, management and directorship experience.
In 2000, Stefan founded BioStatus and since that time has led the company as its CEO. OncoTherics was spun out of BioStatus in 2012. As a founding Director of OncoTherics, Stefan is responsible for the early stage fundraising, direction and strategic management of the business. He is also the President of the newly formed, wholly owned Polish subsidiary company, OncoTherics Poland Sp. zo. o.
Stefan has also been centrally involved in the development of a number of successful life science companies in the UK, including MedilinkEM, BioCity Group, MediCity and Mobius Technology Ventures (BioCity's Life Sciences Investment Fund). He is currently an active Director of BioSuspensions and BioTherics and sits on the advisory panel for the Centre for Doctoral Training in Targeted Therapeutics and Formulation Science at Nottingham University.

l grabarczykLeszek Grabarczyk
has worked in the financing system for the development of technology and commercialization of R&D outcomes for over 15 years. Currently heading Audere Group company specializing in structuring technology development projects in enterprises and helping in winning grants for research and development. At the same time, he is an expert of the European Commission in Horizon 2020. In 2016-2017 he worked for Ernst & Young Business Advisory, providing consultancy, mainly for enterprises, in the area of structuring and financing innovative projects as well as commercializing the results of research and development. Previously, for over 5 years he was the deputy head of the National Center for Research and Development - a governmental agency whose mission is to finance applied research and technology development in enterprises and scientific institutions, and to support commercialization of research results (annual budget 1.5 Billion euro). Previously, he worked in managerial positions at the Ministry of Science and Higher Education. A graduate of the National School of Public Administration (1st place in the ranking).

m tebeauMatthew Tebeau
is the Chief Operating Officer at Proteon Pharmaceuticals, a company developing sustainable technology to prevent anti-microbial resistance and increase agricultural sustainability. Mr. Tebeau joined Proteon in 2012 and is responsible for strategy, investments and partner development. Prior to Proteon, he worked in management and organizational consulting. Mr. Tebeau is also an angel and early stage investor, in addition to biotech he has been involved in a broad variety of technology and consumer services businesses. He is interested in sustainability, disruptive innovation and artificial intelligence. A graduate of Dartmouth College, he has completed post-graduate programs in innovation and cross-cultural management with IMD and Harvard Business School. Mr. Tebeau researched the Solidarity movement in the 1980s in Poland and relocated to Poland in 1990 to participate in the political and economic changes.

a sasAndy Sas-Skowronski
Owner & Managing Director A&C Associates
Andy Skowronski, founder of A&C Associates, is an expert with over 30 years industry experience with organisations such as Pepsico, Yum! Brands and Krispy Kreme. His last role at Yum! Brands (23 years) was as the Director of Supply Chain Management at Yum! Asia, where he was responsible for brand development of Pizza Hut and KFC (a $3.4BN business), developing new growth layers, designing supply and business strategies, leading trade discussions through NGO's at ministerial level and negotiating key contracts (in excess of $500MM). He worked very closely with China and had functional responsibility for India for more than a decade. As a part of the senior executive team, Andy was responsible for developing the regional strategies, which included how a brand is taken to market, selecting franchisees, opening new markets, menu strategies, new sales layers and more...
A&C act as industry advisers to branded food service organisations in the international arena as well as to Private Equity groups such as Cinven, Verny Capital and Alpha One looking to enter or exit the industry. A growing element of his specialism is conducting commercial due diligence work on M&A’s (since March 2013) and has been engaged in due diligence work for Fajr Capital, Actis, McKinsey, BCG, PWC and Abraaj. Andy has also acted as advisor to several major consultancy houses over the years.

f mereauFrançois Mereau
is an active investor in life science companies both at early stages and after their listing, covering the main therapeutic areas. He is a member of the business angels network Angels Santé here he is involved in dealflow selection and due diligence of candidate startups. François has a previous background of 20 years as an institutional investor, on international markets, working with various European banks (Fortis, Compagnie Financière Edmond de Rothschild), fund management companies (FP Consult, Threadneedle Asset Management) and hedge funds (Adelante Asset Management). In these positions, he had the responsibility of leading investment teams and achieving absolute return objectives. François’ current portfolio includes medtech company Cardiawave S.A., gene therapy biotech Theravectys S.A. . as well as Phase 2/3 smoking cessation company NFL BioSciences SAS.

j basonJohn Bason
John has been the manager of PFR Life Science since 2018 and is concerned with assessment of potential investments from a scientific development perspective. Previously he was a Senior Investigative Scientist for the Medical Research Council in Cambridge working on the structure and function of mitochondrial proteins. John has a PhD in Biochemistry from the University of Cambridge and also experience outside of the biotechnology sector working as an advisor to the management board in WB Electronics.

a chabowskiArtur Chabowski
He is a specialist with over 20 years of experience in the field of international investment banking. His career started in the Ministry of Ownership Transformations, later he worked i.a. at CAIB Financial Advisers, KPMG, ABN AMRO Corporate Finance and ACADIA. Mr Artur Chabowski is a graduate of the Faculty of Organisation and Management at the Warsaw University of Technology, moreover, he completed post-graduate studies at the University of Princeton in the Woodrow Wilson School of Public & International Affairs. He has been associated with Mabion and the life science industry since 2009. Presently Artur is CEO of Lipid Systems Sp z o.o..

m borzestowskiMarek Borzestowski
is a CEO of NanoGroup, a holding of biotechnology companies. He is an entrepreneur, manager and founder of numerous innovative companies with over 20 years of experience as a co-owner and board member in leading Polish biotech, IT, and e-commerce companies. After over a decade working as a CEO of a first internet portal in Poland – Wirtualna Polska, he established Polish Israeli VC Giza Polish Ventures. He is a founder of a think tank Sobieski Institute, Startup Hub Poland Foundation. He is a supervisory board member in numerus innovative companies. Marek graduated from the Faculty of Management and Economics at the Gdańsk University of Technology, he also studied at the University of Wales in Great Britain. He conducted a scientific research at the Nuclear Research Center in Karlsruhe and Technical University of Gdansk.

m szubaMarcin Szuba, M.D.
Marcin Szuba is the Fund Manager and founder of the two global healthcare funds at Lartiq TFI. He received a medical degree from the University of Warsaw and a MBA degree from the University of Illinois. He also did training in health policy and economics at the University of Leeds, UK. For six years he worked for the New Zealand government Pharmaceutical Management Agency, Pharmac in Wellington where he was responsible for health technology assessment and pharmaceutical reimbursement contracting in various therapeutic areas such as cardiology, neurology, mental health and respiratory. After returning to Poland in 2008 he joined the largest insurance firm in Poland PZU, where he set up the first global health care fund in Poland EME FIO. In its peak this fund had more than $300m in assets under management. In 2014 he joined the Trigon Group (the winner of the Euromoney Award for Excellence 2018 in the category of Best Investment Bank in Poland) where he currently manages two specialty global closed-end healthcare funds, GFM FIZ and Lartiq TMII FIZ. He is also a board member of numerous health care companies in Poland.

d zietkowskiDominik Zietkowski
is a Project Development Director at BLIRT S.A., a polish innovative biotechnology company located in Gdansk. He received his M.Sc. in biotechnology form the University of Gdansk and a Ph.D. degree in biophysics from the University of London. For 4,5 years he held doctoral and postdoctoral positions at the Institute of Cancer Research and the Royal Marsden Hospital in London where he was working on biomarker discovery and an innovative anticancer compounds development. In 2011 he joined R&D team at Blirt S.A., where he was responsible for the development of company’s in house drug development, R&D projects in oncology and antifungals as well as acting as a CEO in BS-154 sp. z o.o. and Transmedium sp. z o.o., Blirt’s two spin-off companies developing an innovative oncology drug candidate and a transplantology dedicated medical device, respectively. Following Blirt’s strategy shift in 2016 and focus on recombinant protein and enzymes manufacturing he is responsible for projects aimed to develop novel enzymatic products especially for biopharmaceutical and diagnostic applications and also expanding the manufacturing capabilities of the company.

noneDariusz Wiatr
Since 2013 Dariusz has focused on angel investing and advisory work. Within this activity he has been an Advisor to the Polish National Center for Research & Development, the World Bank and the European Commission on matters related to VC investing and technology transfer. He was a founder of Helix Ventures in Warsaw, where he held the role of CEO and Managing Partner and was responsible for deal origination, strategic advisory & investment advisory services. He has been a partner at Hexagon Capital in Warsaw, McKinsey & Company in Warsaw and Andersen Consulting in San Francisco. Earlier in his career he held the position of Vice President at Gemini Consulting in San Francisco. Dariusz has an MBA with distinction from Wharton Business School. He is an internationally recognized figure, and has been extensively quoted in US and Polish business publications including: Boardroom, the Conference Board Magazine, Transformation Magazine, Gazeta Wyborcza, Businessman Magazine and Computerworld.

t fernandezTania Fernandez, Ph.D.
Founder & ceo, dreamcatcher ventures
Dr. Fernandez is the Founder & CEO of DreamCatcher Ventures, San Francisco, CA ( https://www.dreamcatcher.ventures). DreamCatcher Ventures is a strategic advisory services firm based in San Francisco, CA with domain expertise in the Life science, Biotech and Healthcare sectors (therapeutics, diagnostics, medtech and healthcare IT ) that renders strategic advisory services to entrepreneurs, universities, incubators/accelerators and companies in these sectors.
Dr. Fernandez has decades of experience that encompasses scientific and medical research, venture capital, finance and entrepreneurship. She has over 25 years of in-depth experience in the life sciences and over 10 years of venture investing experience with Burrill & Company, San Francisco, CA, a $1.5 B life sciences venture capital fund. As Director she was responsible for sourcing, evaluating, and executing on several successful investment transactions across the Burrill funds. In addition to the US, she also led the firm’s investment strategy for India and cross-border (US-India).
Dr. Fernandez secured her doctorate at the Cancer Research Institute, India, having been awarded the Indo-US scholarship from the National Institutes of Health (NIH), USA. Her research work won her the Young Scientist Award and the most outstanding doctoral thesis award. Her postdoctoral work at the National Cancer Institute, NIH resulted in two awards for excellence in biomedical research. She also completed a post-doctorate in protein chemistry and genetic engineering at the College of Medicine, Texas A&M University. She previously gained operational experience at Hoechst Pharma and currently also runs an immune-oncology start-up.
Combining the worlds of science and business, Tania works with both investors and entrepreneurs and is passionate about helping start-ups assess the commercial relevance of technologies, evaluate business models, generate strategic and financial road maps and understand the financing landscape. She works with several international markets . She is also heavily focused on fostering the innovation ecosystem and works extensively with entrepreneurs and several commercialization of innovation programs across the United States. She has been/is a mentor/investor coach/judge to UCSF, UC Davis, Harvard University and Berkeley. She was co-instructor at UCSF’s “An Idea to IPO and beyond” course and mentor at Steve Blank’s “Lean Launch Pad for Start-ups”.
Dr Fernandez is also a Managing Partner with BSD Growth Fund, a venture fund whose mission is to work with entrepreneurs to create and develop world class healthcare companies by funding promising and disruptive healthcare technologies, that are initially nurtured and grown in Poland while seeking global markets.

s ChoudharySanjeev Choudhary
Sanjeev Choudhary is the Founder, Chief Executive Officer of Medinice SA since its very inception in 2012. Sanjeev holds more than 22 years of professional experience in various specialization including M&A transactions through out Europe. Since 1996 Sanjeev is serving as Management Board Member and Supervisory boards in multiple companies.
During the course of last 10-12 years, he has launched and funded several startups, a few of which exited through listings in Warsaw stock exchange. Sanjeev holds an engineering degree in IT and MBA. Further he pursued his education in several renowned institutions like Ashridge Business School, Centre for Creative Leadership and INSEAD where he joined M&A and Corporate Strategy programme. Prior to inception of Medinice SA, Sanjeev was engaged with Orkla Media, a Norwegian conglomerate listed on Oslo Stock Exchange, where he served on several top management positions in Poland, Denmark as well as Lithuania.